Alnylam (ALNY) Turns Profitable as Revenue Mix Shifts: What Changes in Its Investment Story?
- In the second quarter of 2026, Alnylam Pharmaceuticals reported revenue of US$1,290.95 million and net income of US$164.49 million, marking a shift from a loss a year earlier, and also showed much higher revenue and profitability for the first half of the year.
- Alongside these results, the company trimmed its full‑year net product revenue outlook while increasing expectations for collaboration and royalty revenue, highlighting a changing mix in how it generates sales.
- Next, we’ll examine how this sharp move to profitability and revised full‑year revenue mix guidance shapes Alnylam’s existing investment narrative.
Find 53 companies with promising cash flow potential yet trading below their fair value.
Alnylam Pharmaceuticals Investment Narrative Recap
To own Alnylam, you need to believe RNAi medicines can support a profitable, growing business despite pricing pressure, heavy R&D needs, and dependence on its TTR franchise. The sharp move to profitability in Q2 2026 and the revised mix toward higher collaboration and royalty revenue do not fundamentally change that narrative, but they do make near term execution on TTR and payer dynamics even more important, while cost discipline and pricing pressure remain key risks.
The most relevant recent announcement is the July 2026 guidance update, which lowered full year net product revenue expectations to US$4,700 million to US$5,100 million while raising collaboration and royalty revenue guidance to US$575 million to US$625 million. For investors watching TTR franchise concentration risk and pricing pressure, this shift in revenue mix adds another layer to how sustainable the current profitability profile may prove to be over time.
Yet even as earnings improve, investors should be aware that concentrated reliance on the TTR franchise could become a problem if...
Read the full narrative on Alnylam Pharmaceuticals (it's free!)
Alnylam Pharmaceuticals' narrative projects $9.0 billion revenue and $2.0 billion earnings by 2029. This requires 28.3% yearly revenue growth and an earnings increase of about $1.5 billion from $538.0 million today.
Uncover how Alnylam Pharmaceuticals' forecasts yield a $434.72 fair value, a 97% upside to its current price.
Exploring Other Perspectives
Before this earnings beat, the most optimistic analysts were projecting about 40 percent annual revenue growth and earnings near US$3.6 billion by 2029, so compared with baseline concerns about pricing pressure, they paint a far more upbeat path that Q2 results and updated guidance may either reinforce or challenge as you weigh different viewpoints.
Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth just $305.63!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.
Searching For A Fresh Perspective?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com